Compare PAVM & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PAVM | SCYX |
|---|---|---|
| Founded | 2014 | 1999 |
| Country | United States | United States |
| Employees | 41 | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.1M | 37.0M |
| IPO Year | N/A | 2014 |
| Metric | PAVM | SCYX |
|---|---|---|
| Price | $5.11 | $5.23 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $65.00 | $3.00 |
| AVG Volume (30 Days) | 8.6K | ★ 231.6K |
| Earning Date | 05-15-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.36 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $257,000.00 |
| Revenue This Year | $603.94 | N/A |
| Revenue Next Year | $33.16 | $608.78 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.21 | $0.57 |
| 52 Week High | $28.44 | $5.62 |
| Indicator | PAVM | SCYX |
|---|---|---|
| Relative Strength Index (RSI) | 44.60 | 65.23 |
| Support Level | $4.45 | $0.65 |
| Resistance Level | $6.56 | $5.62 |
| Average True Range (ATR) | 0.46 | 0.45 |
| MACD | -0.01 | 0.11 |
| Stochastic Oscillator | 37.46 | 83.08 |
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, EsoCheck, and the Veris Cancer Care Platform.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.